Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.
Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.
The effects of sleep deprivation on cognitive function may be reversed by treatment with a compound called orexin-A, which occurs naturally in the mammalian brain. The new research was done with ...